This is just the beginning! Our collection holds over 300 years of history, including rare newspapers, obituaries, marriage records, birth records, and so much more—most of which you won’t find anywhere else!
FDA approves controversial Alzheimer's drug Aduhelm
The FDA approves Biogen and Eisai's aducanumab for Alzheimer’s under accelerated rules despite advisers’ warnings that it may not slow progression. The drug aims to clear beta amyloid deposits, with follow up studies required to confirm benefits and a high price tag sparking debate over value and access.
MENTIONED IN THIS ARTICLE
Washington
Food and Drug Administration
Biogen
Japan
Eisai Co
Caleb Alexander
FDA
Cambridge
Institute For Clinical and Economic Review